University of Minnesota
University Relations
http://www.umn.edu/urelate
612-624-6868
University of Minnesota
POLICY LIBRARY
POLICY
University of Minnesota
University of Minnesota
University M logo on red background
ADMINISTRATIVE POLICY

Reporting Sponsor-Investigator Investigational New Drug Applications (IND) or Investigational Device Exemption (IDE)

Effective Date: November 2003
Last Update: November 2003
Responsible University Officer:
  • Vice President for Research
Policy Owner:
  • Director - Research Education and Oversight, OVPR
Policy Contact:

Printed on: . Please go to http://policy.umn.edu for the most current version of the Policy or related document.

POLICY STATEMENT

All University faculty members who file an Investigational New Drug Application (IND) or Investigational Device Exemption (IDE) with the Food and Drug Administration (FDA) as a sponsor-investigator must submit all documents relevant to the IND/IDE to a University documentation unit (a central file).

Documents to be kept by the IND/IDE Documentation Unit include the application, communications, safety reports, amendments, and annual reports. These documents will be used to remind and assist sponsor-investigators of their reporting obligations to the FDA and to track reports and communications with the FDA. The IND/IDE Documentation Unit will not ascertain compliance, but will assist sponsor-investigators to be compliant.

This policy applies only when faculty members serve as the sponsor of an IND or IDE. It does not apply to the more common situation when a faculty member serves only as the principal investigator on an IND or IDE and the sponsor is a pharmaceutical, biotechnology, or medical device company.

REASON FOR POLICY

FDA regulations are complex and difficult to interpret. The FDA is continually issuing updates and new guidance documents. It is difficult and time consuming to keep abreast of the changes to the regulations. The regulations require that certain obligations be met at specific times. Proper adherence to FDA regulations is critical to managing risk. The FDA will not directly communicate with the University regarding a sponsor-investigator's IND or IDE. The University, however, is potentially liable for the actions of its faculty members.

In order to ascertain compliance with FDA regulations, the IND/IDE Documentation Unit will receive information from faculty members and from other units such as the IRB and Office of Regulatory Affairs. The IND/IDE Documentation Unit will notify sponsor-investigators when reporting obligations need to be met. If sponsor-investigators fail to comply with FDA regulations, the Office of Regulatory Affairs and other appropriate institutional offices will be notified.

PROCEDURES

FORMS/INSTRUCTIONS

There are no forms associated with this policy.

APPENDICES

FREQUENTLY ASKED QUESTIONS

There is no FAQ associated with this policy.

ADDITIONAL CONTACTS

Subject
Contact
Phone
Fax/Email
Primary Contact(s)
612-624-8349
Program Background
IND/IDE Program
612-625-0930
612-625-3956 (fax)

DEFINITIONS

Food and Drug Administration
The regulatory authority in the United States which oversees the pharmaceutical and medical device industries. The FDA is responsible for ensuring that the drugs and medical devices marketed in the US have a greater benefit than risk when used according to manufacturer's directions.
IND/IDE Assistance Program
A unit of the Academic Health Center under the supervision of the Assistant Vice President for Research, AHC. The IND/IDE Assistance Program provides free, optional assistance to faculty members who are submitting an IND or IDE to the FDA (or require advice as to whether an IND or IDE is required). The IND/IDE Assistance Program will operate the IND/IDE Documentation Unit as an obligatory requirement for all sponsor-investigators of an IND or IDE.
Investigational device exemption (IDE)
Document submitted to the FDA to allow for the conduct of a clinical study using a significant risk device that is new or not approved for that use.
Investigational new drug application (IND)
Document submitted to the Food and Drug Administration (FDA) to allow for the conduct of a clinical study using a drug that is new or not approved for that dosage form or indication.
Investigator
An individual who actually conducts a clinical investigation.
Sponsor
A person who takes responsibility for and initiates a clinical investigation. (This is often a pharmaceutical, biotechnology, or medical device company).
Sponsor-Investigator
An individual (not a company) who both initiates and conducts an investigation and complies with all the obligations of both a sponsor and an investigator.

RESPONSIBILITIES

Sponsor-investigator
Submit copies of all relevant documents (IND or IDE application, all communications to and from the FDA, safety reports, protocol amendments, and annual reports) to the Documentation Unit
IND/IDE Assistance Program
Assist faculty members in determining whether an IND or IDE application to the FDA is required. Provide optional assistance in preparing an IND or IDE. Operate the IND/IDE Documentation Unit.
IND/IDE Documentation Unit
Maintain a central file (copies) of all documents relevant to a sponsor-investigator IND or IDE held by a faculty member. Remind sponsor-investigators when (annual) reports or other communications with the FDA are required. Report suspected or known instances of noncompliance with University, FDA, or other applicable policies to the Office of Regulatory Affairs for investigation and resolution.

RELATED INFORMATION

HISTORY

Effective:
November 2003

Document Feedback

Did this document successfully answer your questions?

Additional comments: (2000 character limit)

Email Address: (so we can respond to your questions)

© 2013 Regents of the University of Minnesota. All rights reserved.
The University of Minnesota is an equal opportunity educator and employer.
Last modified on October 21, 2013